00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Basilea, Asahi Kasei Pharma deal

Basilea granted Asahi exclusive rights in Japan to develop and commercialize isavuconazole. Basilea will receive CHF7 million ($7.2 million) up front and is eligible for up to CHF60 million ($61.6 million) in milestones, plus double-digit...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Basilea, Grupo Biotoscana deal

Basilea granted Grupo Biotoscana exclusive rights to commercialize Cresemba isavuconazole and Zevtera ceftobiprole in 19 Latin American countries, including Argentina, Brazil, Columbia and Mexico. Basilea will receive CHF11 million ($11.3 million) up front and is...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Company News

Basilea sales and marketing update

Basilea launched Cresemba isavuconazole in the U.K. and Germany to treat invasive aspergillosis and mucormycosis in patients for whom treatment with amphotericin B is not appropriate. The NHS list-price of the broad-spectrum, water-soluble azole antifungal...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

Cresemba isavuconazonium regulatory update

The European Commission approved an MAA from Basilea for Cresemba isavuconazonium to treat adults with invasive aspergillosis and adults with mucormycosis for whom amphotericin B is not appropriate. Basilea expects to launch the broad-spectrum water-soluble...
01:30 , Oct 17, 2015 |  BC Extra  |  Company News

EC approves Basilea's Cresemba

Basilea Pharmaceutica AG (SIX:BSLN) said the European Commission approved an MAA for Cresemba isavuconazonium to treat adults with invasive aspergillosis and adults with mucormycosis for whom amphotericin B is not appropriate. Basilea said it expects...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Event planner

For investors who are not inclined to sit it out until the volatility abates, the fourth quarter is bursting with late-stage catalysts. There are no fewer than 17 PDUFA dates on the calendar before year...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Drawn and quartered

There was no joy to be had in 3Q15, as every biotech market cap band fell by at least 15%. After the carnage only one group - companies valued north of $5 billion - are...